Compare Ascendis Pharma A/S (ASND) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs International Business Machines Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while International Business Machines Corp trades at $288.8 (market cap $270.27B). The key difference: International Business Machines Corp is far larger — about 15.2× Ascendis Pharma A/S's market cap, and International Business Machines Corp pays a 2.35% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | IBM | |
|---|---|---|
Market Cap | $17.74B | $270.27B |
Sector | Health | Technology |
52-Week High | $277.18 | $329.23 |
52-Week Low | $163.32 | $214.64 |
Enterprise Value | $18.11B | $328.29B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IBM trades at $287.56, down 2.62% today, near key support at $288. The stock shows strong fundamentals with revenue growth to $67.54B in 2025 and net income margin of 15.61%. Recent quarterly earnings consistently beat estimates, and the technical outlook is bullish with moving averages signaling upward momentum. Analyst consensus price target is $309.07, suggesting potential upside from current levels.
Outlook remains positive driven by enterprise AI and quantum computing initiatives, though risks include competitive pressures in software and reliance on legacy systems. Wall Street sentiment is mixed with 47% buy ratings, but institutional interest remains strong. The upcoming Q2 2026 earnings report on July 22 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
